William Feldman: Looking at payer-negotiated prices on oncology drugs at pediatric 340B hospitals
William Feldman, Assistant Professor at Harvard Medical School and Ethics Co-Chair at Brigham and Women’s Hospital, shared a post by Program On Regulation, Therapeutics, And Law, on X, adding:
”We have a new paper out looking at payer-negotiated prices on oncology drugs at pediatric 340B hospitals. Led by Program On Regulation, Therapeutics, And Law‘s Ian Liu and Aviva Wang.”
Quoting Program On Regulation, Therapeutics, And Law’s post:
”NEW: Analysis led by Ian Liu examines oncology drug mark-ups at 340B pediatric hospitals. These hospitals can extract steep payments for these drugs from commercial insurers, with median payments ranging from 102-630% of the average sales price.”
Source: William Feldman/X and Program On Regulation, Therapeutics, And Law/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023